Osmotica Pharmaceuticals (NASDAQ:OSMT) Lifted to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a sell rating to a hold rating in a research note released on Saturday, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Several other equities analysts have also issued reports on the company. BidaskClub lowered Osmotica Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, October 15th. Wells Fargo & Company reaffirmed a hold rating on shares of Osmotica Pharmaceuticals in a research report on Thursday, September 3rd. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Osmotica Pharmaceuticals has a consensus rating of Hold and a consensus target price of $8.70.

Shares of OSMT stock opened at $6.15 on Friday. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.17 and a quick ratio of 2.83. The stock has a market cap of $316.85 million, a PE ratio of -2.10 and a beta of 3.27. The stock has a 50-day moving average of $5.78 and a 200-day moving average of $5.67. Osmotica Pharmaceuticals has a one year low of $2.81 and a one year high of $9.67.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.06. Osmotica Pharmaceuticals had a negative return on equity of 15.61% and a negative net margin of 73.47%. The business had revenue of $57.17 million during the quarter, compared to analyst estimates of $36.54 million. As a group, research analysts anticipate that Osmotica Pharmaceuticals will post -0.59 earnings per share for the current year.

Hedge funds have recently modified their holdings of the business. American International Group Inc. boosted its position in shares of Osmotica Pharmaceuticals by 40.2% during the second quarter. American International Group Inc. now owns 7,308 shares of the company’s stock valued at $49,000 after buying an additional 2,094 shares during the last quarter. First Trust Advisors LP boosted its position in Osmotica Pharmaceuticals by 9.4% in the second quarter. First Trust Advisors LP now owns 28,344 shares of the company’s stock worth $191,000 after purchasing an additional 2,447 shares during the last quarter. State of Wisconsin Investment Board boosted its position in Osmotica Pharmaceuticals by 27.0% in the second quarter. State of Wisconsin Investment Board now owns 15,500 shares of the company’s stock worth $104,000 after purchasing an additional 3,300 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Osmotica Pharmaceuticals by 4.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 94,977 shares of the company’s stock worth $514,000 after purchasing an additional 3,644 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Osmotica Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 28,642 shares of the company’s stock worth $192,000 after purchasing an additional 6,312 shares during the last quarter. Institutional investors and hedge funds own 11.89% of the company’s stock.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity.

Recommended Story: Day Trading

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply